Clinical trials testing β3-AR agonists for obesity showed minimal efficacy, while highlighting safety concerns [17,18,19], likely due to significantly lower β3-AR expression in human adipocytes [20,21]. This evidence concerns the gene ADRB3 and obesity disorder.